Form 4: Fibrogen CEO Reports Stock Transaction
Insider Transaction (Form 4)
Thane Wettig, CEO and a Director of Fibrogen Inc, reported a transaction in 209 shares of common stock on September 6, 2026.
Summary
- Tax/exercise-price withholding: disposed of 209 Common Stock at $8.55 ($1,787) on September 6, 2026; holds 26,796 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Thane Wettig — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-06 | Tax/exercise-price withholding | Common Stock | 209 | $9 | $1.8K | 26,796 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-06 | Tax/exercise-price withholding (209 shares) |
Keywords
insider transaction, Form 4, KYNB, KYNTRA BIO, INC., neutral, Thane Wettig
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.